Highlights
IIA supported (ever)
About
Automated Platform for Autologous Cell Manufacturing
ADVA Biotechnology develops enabling technologies for cell therapy manufacturing. The company has developed ADVA X3, a robust, modular cell-manufacturing cGMP system based on a single-use end-to-end solution. ADVA X3 enables autologous cell therapy manufacturing at the bedside, allowing optimization, tight quality assurance, improved availability, reduced time to market, and significant cost reduction. The automated platform is designed to enable autologous manufacturing of additional types of cells with a change in the disposable chamber, allowing efficiency and flexibility with a long pipeline of products.
Identity
| Name | ADVA Biotechnology |
|---|---|
| Slug | adva-biotechnology |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4LbKhrIJDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | פארק תעשיות בר-לב |
| HQ address | Bar Lev Industrials Park, Israel |
Web & social
| Website | https://www.advabio.com/ |
|---|---|
| Careers page | https://www.advabio.com |
| https://www.linkedin.com/company/30096447 | |
| YouTube | https://www.youtube.com/channel/UC-MHD-u3j_vRlBMmK-W8Ndg |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesHealthcareProvidersLife SciencesPharmaceuticals
Business models
B2B
Tags
medical-technologiespatientsbiotechnologymedical-deviceshospitalscancercell-therapyimmunologymanufacturinggenetic-engineeringautomationmonitoring
Funding
| Total raised | $385K |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}